Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Enrollment completed in phase I Biomira lung cancer vaccine trial

Dec. 4, 1998

MDX-210 demonstrates antitumor activity in phase II studies

Dec. 4, 1998

Vical provides clinical update of Leuvectin in treatment of prostate cancer

Dec. 2, 1998

Neurocrine Biosciences advances development of NBI-3001

Nov. 30, 1998

Cell Genesys broadens GVAX trials program in prostate cancer

Nov. 30, 1998

B43-PAP: a promising treatment for Ph+ ALL in development at Hughes Institute

Nov. 30, 1998

PEG-Intron A advances to phase III trials for chronic myelogenous leukemia

Nov. 25, 1998

Novopharm Biotech completes patient enrollment for phase I study of NOVOMAb-G2

Nov. 23, 1998

New U.S. patent provides protection for improved Avicine formulations

Nov. 20, 1998

Vical provides clinical update of Allovectin-7 in treatment of head and neck cancer

Nov. 18, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...